Laboratorios Farmaceuticos Rovi S.A.
ISIN: ES0157261019 | Ticker: ROVI | LEI: 95980020140005936480
Country: Spain
ROVI is a fully integrated Spanish specialty pharmaceutical company engaged in the research, development, in-licensing, manufacturing and marketing of small molecule and specialty biologic drugs.
To date, thanks to our 22 alliances with international partners, our principal product, Bemiparin, is now present in more than 55 countries.
With our Enoxaparin Biosimilar, we hope to increase our presence in Europe, the United States and emerging countries.
1946
Served areaWorldwide
Headcount1,209
HeadquartersCl Julian Camarillo 35, 28037 Madrid – Spain
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 574,439,000.00 | 732,676,000.00 | 878,703,000.00 |
| Noncurrent Assets | N/A | 209,861,000.00 | 226,314,000.00 | 255,630,000.00 |
| Property Plant And Equipment | N/A | 155,395,000.00 | 181,775,000.00 | 215,541,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 41,413,000.00 | 38,558,000.00 | 35,744,000.00 |
| Investments In Joint Ventures Accounted For Using Equity Method | N/A | 1,812,000.00 | 1,994,000.00 | 2,193,000.00 |
| Noncurrent Receivables | N/A | 65,000.00 | 65,000.00 | 65,000.00 |
| Deferred Tax Assets | N/A | 11,105,000.00 | 3,850,000.00 | 2,078,000.00 |
| Noncurrent Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income | N/A | 71,000.00 | 72,000.00 | 9,000.00 |
| Current Assets | N/A | 364,578,000.00 | 506,362,000.00 | 623,073,000.00 |
| Inventories | N/A | 227,199,000.00 | 245,473,000.00 | 311,944,000.00 |
| Trade And Other Current Receivables | N/A | 76,401,000.00 | 150,172,000.00 | 180,011,000.00 |
| Current Prepaid Expenses | N/A | 13,000.00 | 1,791,000.00 | 2,025,000.00 |
| Current Tax Assets Current | N/A | 7,803,000.00 | 9,891,000.00 | 4,148,000.00 |
| Cash and cash equivalents | 67,426,000.00 | 53,162,000.00 | 99,035,000.00 | 124,945,000.00 |
| Equity And Liabilities | N/A | 574,439,000.00 | 732,676,000.00 | 878,703,000.00 |
| Equity | 322,386,000.00 | 373,700,000.00 | 470,976,000.00 | 521,379,000.00 |
| Issued Capital | N/A | 3,364,000.00 | 3,364,000.00 | 3,241,000.00 |
| Share Premium | N/A | 87,636,000.00 | 87,636,000.00 | 87,636,000.00 |
| Treasury Shares | N/A | 20,185,000.00 | 66,121,000.00 | 27,561,000.00 |
| Other Reserves | N/A | -3,000.00 | -2,000.00 | N/A |
| Statutory Reserve | N/A | 673,000.00 | 673,000.00 | 673,000.00 |
| Equity Attributable To Owners Of Parent | N/A | N/A | 470,976,000.00 | 520,012,000.00 |
| Noncontrolling Interests | N/A | N/A | 0.00 | 1,367,000.00 |
| Liabilities | N/A | 200,739,000.00 | 261,700,000.00 | 357,324,000.00 |
| Noncurrent Liabilities | N/A | 77,850,000.00 | 71,312,000.00 | 63,437,000.00 |
| Noncurrent Contract Liabilities | N/A | 5,788,000.00 | 1,460,000.00 | 1,545,000.00 |
| Noncurrent Deferred Income Other Than Noncurrent Contract Liabilities | N/A | N/A | 2,331,000.00 | 1,774,000.00 |
| Deferred Tax Liabilities | N/A | 929,000.00 | 776,000.00 | 677,000.00 |
| Longterm Borrowings | N/A | 68,421,000.00 | 66,745,000.00 | 59,441,000.00 |
| Current Liabilities | N/A | 122,889,000.00 | 190,388,000.00 | 293,887,000.00 |
| Trade And Other Current Payables | N/A | 91,364,000.00 | 125,173,000.00 | 165,776,000.00 |
| Current Contract Liabilities | N/A | 25,005,000.00 | 57,632,000.00 | 114,901,000.00 |
| Current Deferred Income Other Than Current Contract Liabilities | N/A | N/A | 485,000.00 | 485,000.00 |
| Current Tax Liabilities Current | N/A | 0.00 | 681,000.00 | 0.00 |
| Current Borrowings And Current Portion Of Noncurrent Borrowings | N/A | 6,022,000.00 | 6,417,000.00 | 12,725,000.00 |
| Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 419,961,000.00 | 648,677,000.00 | 817,698,000.00 |
| Changes In Inventories Of Finished Goods And Work In Progress | -17,659,000.00 | -782,000.00 | -38,883,000.00 |
| Other Work Performed By Entity And Capitalised | N/A | 0.00 | 2,856,000.00 |
| Employee Benefits Expense | 74,429,000.00 | 89,803,000.00 | 106,522,000.00 |
| Depreciation And Amortisation Expense | 19,593,000.00 | 21,364,000.00 | 22,871,000.00 |
| Profit Loss From Operating Activities | 74,682,000.00 | 181,392,000.00 | 255,848,000.00 |
| Finance Income | 4,000.00 | 68,000.00 | 1,770,000.00 |
| Finance Costs | 1,072,000.00 | 905,000.00 | 849,000.00 |
| Profit Loss Before Tax | 72,581,000.00 | 182,628,000.00 | 257,967,000.00 |
| Income Tax Expense Continuing Operations | 11,524,000.00 | 29,551,000.00 | 58,302,000.00 |
| Profit (loss) | 61,057,000.00 | 153,077,000.00 | 199,665,000.00 |
| Profit Loss Attributable To Owners Of Parent | N/A | 153,077,000.00 | 199,669,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | N/A | 0.00 | -4,000.00 |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | 61,057,000.00 | 153,077,000.00 | 199,665,000.00 |
| Adjustments For Finance Costs | N/A | 1,072,000.00 | 905,000.00 | 849,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | -70,398,000.00 | -23,427,000.00 | -71,591,000.00 |
| Adjustments For Depreciation And Amortisation Expense | N/A | 19,593,000.00 | 21,364,000.00 | 22,871,000.00 |
| Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | N/A | 1,772,000.00 | 4,885,000.00 | 5,160,000.00 |
| Adjustments For Unrealised Foreign Exchange Losses Gains | N/A | N/A | 0.00 | 821,000.00 |
| Adjustments For Sharebased Payments | N/A | 0.00 | 1,403,000.00 | 0.00 |
| Interest Paid Classified As Operating Activities | N/A | 151,000.00 | 4,000.00 | 0.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | -6,038,000.00 | -23,861,000.00 | -43,889,000.00 |
| Cash Flows From Used In Operating Activities | N/A | 46,876,000.00 | 149,441,000.00 | 237,602,000.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | N/A | 63,000.00 | 33,000.00 | 78,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 39,337,000.00 | 40,218,000.00 | 50,719,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 355,000.00 | 722,000.00 | 669,000.00 |
| Interest Paid Classified As Investing Activities | N/A | 299,000.00 | 288,000.00 | N/A |
| Interest Received Classified As Investing Activities | N/A | 4,000.00 | 68,000.00 | 6,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -39,625,000.00 | -40,839,000.00 | -57,154,000.00 |
| Proceeds From Issuing Other Equity Instruments | N/A | N/A | 0.00 | 1,371,000.00 |
| Payments To Acquire Or Redeem Entitys Shares | N/A | 37,255,000.00 | 78,785,000.00 | 177,008,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 1,430,000.00 | 1,340,000.00 | 1,399,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 13,179,000.00 | 6,192,000.00 | 6,768,000.00 |
| Dividends Paid Classified As Financing Activities | N/A | 9,700,000.00 | 21,132,000.00 | 51,007,000.00 |
| Interest Paid Classified As Financing Activities | N/A | N/A | 288,000.00 | 291,000.00 |
| Cash Flows From Used In Financing Activities | N/A | -21,515,000.00 | -62,729,000.00 | -154,538,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | -14,264,000.00 | 45,873,000.00 | 25,910,000.00 |
| Cash and cash equivalents | 67,426,000.00 | 53,162,000.00 | 99,035,000.00 | 124,945,000.00 |
Please note that some sums might not add up.
ES0157261019
LEI95980020140005936480
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryIBEX35
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.